Viracept Patent Expiration

Viracept is a drug owned by Agouron Pharmaceuticals Llc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 07, 2014. Details of Viracept's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6162812

(Pediatric)

Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
Apr, 2014

(10 years ago)

Expired
US5952343

(Pediatric)

HIV protease inhibitors
Apr, 2014

(10 years ago)

Expired
US5484926

(Pediatric)

HIV protease inhibitors
Apr, 2014

(10 years ago)

Expired
US5952343 HIV protease inhibitors
Oct, 2013

(11 years ago)

Expired
US6162812 Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
Oct, 2013

(11 years ago)

Expired
US5484926 HIV protease inhibitors
Oct, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Viracept is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Viracept's family patents as well as insights into ongoing legal events on those patents.

Viracept's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Viracept's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 07, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Viracept Generics:

There are no approved generic versions for Viracept as of now.

Alternative Brands for Viracept

Viracept which is used for managing HIV infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbvie
Kaletra used for treating HIV-1 infection in combination with other antiretroviral agents.
Bristol Myers Squibb
Sustiva used for managing HIV infection in combination with other antiviral drugs.
Gilead
Emtriva Used for treating HIV infection in adults.
Truvada Used for treating HIV-1 infection in adults and pediatric patients.
Gilead Sciences
Atripla Used for managing HIV-1 infection in adults and pediatric patients aged 12 years and older.
Gilead Sciences Inc
Viread used for managing chronic hepatitis B and HIV infections in both adults and pediatric patients.
Descovy Used for managing and treating HIV infection.
Genvoya Used for treating HIV infection with a composition containing a pharmacokinetic enhancer that inhibits cytochrome P450 monoxygenase.
Odefsey Used for treating HIV infection.
Vitekta Used for managing HIV infection.
Biktarvy Used for treating HIV infection.
Complera Used for managing and treating HIV infection.
Stribild Used for treating HIV infection by enhancing the pharmacokinetics and inhibiting cytochrome P450 monooxygenase.
Glaxosmithkline
Agenerase Used for managing HIV infection.
Msd Sub Merck
Isentress Used for treating HIV infection by inhibiting integrase.
Isentress Hd Used for treating HIV infection.
Roche
Fuzeon Used for managing HIV infection.
Viiv Hlthcare
Dovato Used for the treatment of HIV infection.
Epivir Used for treating HIV infection.
Juluca Used for managing HIV infection.
Lexiva Used for managing and treating HIV infection.
Epzicom Used for treating HIV infection.
Combivir Used for the treatment of HIV.
Trizivir Used for treating patients infected with HIV.





About Viracept

Viracept is a drug owned by Agouron Pharmaceuticals Llc. It is used for managing HIV infection. Viracept uses Nelfinavir Mesylate as an active ingredient. Viracept was launched by Agouron Pharms in 1997.

Approval Date:

Viracept was approved by FDA for market use on 14 March, 1997.

Active Ingredient:

Viracept uses Nelfinavir Mesylate as the active ingredient. Check out other Drugs and Companies using Nelfinavir Mesylate ingredient

Treatment:

Viracept is used for managing HIV infection.

Dosage:

Viracept is available in the following dosage forms - tablet form for oral use, powder form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 250MG BASE TABLET Prescription ORAL
EQ 625MG BASE TABLET Prescription ORAL
EQ 50MG BASE/SCOOPFUL POWDER Discontinued ORAL